Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


18.09.2017

1 Br J Cancer
4 Cancer
2 Cancer Lett
2 Cancer Res
3 Clin Cancer Res
3 Eur Urol
2 Hum Pathol
3 Int J Urol
1 Invest Radiol
1 J Magn Reson Imaging
1 J Nucl Med
11 J Urol
2 Nat Rev Urol
1 Oncol Rep
4 PLoS One
1 Proc Natl Acad Sci U S A
4 Prostate
1 Urol Int
2 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Br J Cancer

  1. PEREZ-CORNAGO A, Key TJ, Allen NE, Fensom GK, et al
    Prospective investigation of risk factors for prostate cancer in the UK Biobank cohort study.
    Br J Cancer. 2017 Sep 14. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    Cancer

  2. MEDHANIE GA, Fedewa SA, Adissu H, DeSantis CE, et al
    Cancer incidence profile in sub-Saharan African-born blacks in the United States: Similarities and differences with US-born non-Hispanic blacks.
    Cancer. 2017;123:3116-3124.
    PubMed     Text format     Abstract available

  3. LOPPENBERG B, Friedlander DF, Krasnova A, Tam A, et al
    Variation in the use of active surveillance for low-risk prostate cancer.
    Cancer. 2017 Sep 13. doi: 10.1002/cncr.30983.
    PubMed     Text format     Abstract available

  4. JAGAI JS, Messer LC, Rappazzo KM, Gray CL, et al
    County-level cumulative environmental quality associated with cancer incidence.
    Cancer. 2017;123:2901-2908.
    PubMed     Text format     Abstract available

  5. GORE JL, du Plessis M, Santiago-Jimenez M, Yousefi K, et al
    Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PRO-IMPACT study.
    Cancer. 2017;123:2850-2859.
    PubMed     Text format     Abstract available


    Cancer Lett

  6. QIN F, Zhang Y, Liu J, Li H, et al
    SLC45A3-ELK4 functions as a long non-coding chimeric RNA.
    Cancer Lett. 2017;404:53-61.
    PubMed     Text format     Abstract available

  7. BASHARI O, Redko B, Cohen A, Luboshits G, et al
    Discovery of peptide drug carrier candidates for targeted multi-drug delivery into prostate cancer cells.
    Cancer Lett. 2017 Sep 6. pii: S0304-3835(17)30535.
    PubMed     Text format     Abstract available


    Cancer Res

  8. LOVERIDGE CJ, Mui EJ, Patel R, Tan EH, et al
    Increased T-cell Infiltration Elicited by Erk5 Deletion in a Pten-Deficient Mouse Model of Prostate Carcinogenesis.
    Cancer Res. 2017;77:3158-3168.
    PubMed     Text format     Abstract available

  9. IBRAHIM-HASHIM A, Robertson-Tessi M, Enriquez-Navas PM, Damaghi M, et al
    Defining Cancer Subpopulations by Adaptive Strategies Rather Than Molecular Properties Provides Novel Insights into Intratumoral Evolution.
    Cancer Res. 2017;77:2242-2254.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  10. KETOLA K, Munuganti RS, Davies A, Nip KM, et al
    Targeting Prostate Cancer Subtype 1 by Forkhead box M1 Pathway Inhibition.
    Clin Cancer Res. 2017 Sep 12. pii: clincanres.0901.2017.
    PubMed     Text format     Abstract available

  11. LABBE DP, Sweeney CJ, Brown M, Galbo P, et al
    TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup.
    Clin Cancer Res. 2017 Sep 12. pii: clincanres.0413.2017.
    PubMed     Text format     Abstract available

  12. CALAGUA C, Russo J, Sun Y, Schaefer R, et al
    Expression of PD-L1 in Hormone-naive and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide.
    Clin Cancer Res. 2017 Sep 11. pii: clincanres.0807.2017.
    PubMed     Text format     Abstract available


    Eur Urol

  13. DAL PRA A, Supiot S, Ghadjar P
    Re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. Eur
    Eur Urol. 2017 Sep 7. pii: S0302-2838(17)30718.
    PubMed     Text format    

  14. SEISEN T, Vetterlein MW, Karabon P, Jindal T, et al
    Efficacy of Local Treatment in Prostate Cancer Patients with Clinically Pelvic Lymph Node-positive Disease at Initial Diagnosis.
    Eur Urol. 2017 Sep 7. pii: S0302-2838(17)30697.
    PubMed     Text format     Abstract available

  15. GANDAGLIA G, Fossati N, Montorsi F, Briganti A, et al
    Reply to Alan Dal Pra, Stephane Supiot and Pirus Ghadjar's Letter to the Editor re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen Afte
    Eur Urol. 2017 Sep 7. pii: S0302-2838(17)30719.
    PubMed     Text format    


    Hum Pathol

  16. DE VIVAR AD, Sayeeduddin M, Rowley D, Cubilla A, et al
    Histologic features of stromogenic carcinoma of the prostate (carcinomas with reactive stroma grade 3).
    Hum Pathol. 2017;63:202-211.
    PubMed     Text format     Abstract available

  17. GILANI S, Guo CC, Li-Ning EM, Pettaway C, et al
    Transformation of prostatic adenocarcinoma to well-differentiated neuroendocrine tumor after hormonal treatment.
    Hum Pathol. 2017;64:186-190.
    PubMed     Text format     Abstract available


    Int J Urol

  18. YANO A, Kagawa M, Takeshita H, Okada Y, et al
    Baseline low serum dehydroepiandrosterone sulfate can predict poor responsiveness to hormone therapy in patients with hormone-naive prostate cancer with skeletal metastases.
    Int J Urol. 2017 Sep 11. doi: 10.1111/iju.13445.
    PubMed     Text format    

  19. SAIKA T, Miura N, Fukumoto T, Yanagihara Y, et al
    Role of robot-assisted radical prostatectomy in locally advanced prostate cancer.
    Int J Urol. 2017 Sep 13. doi: 10.1111/iju.13441.
    PubMed     Text format     Abstract available

  20. PEREIRA-AZEVEDO N, Braga I, Verbeek JF, Osorio L, et al
    Prospective evaluation on the effect of interobserver variability of digital rectal examination on the performance of the Rotterdam Prostate Cancer Risk Calculator.
    Int J Urol. 2017 Sep 13. doi: 10.1111/iju.13442.
    PubMed     Text format     Abstract available


    Invest Radiol

  21. PEREZ-LOPEZ R, Nava Rodrigues D, Figueiredo I, Mateo J, et al
    Multiparametric Magnetic Resonance Imaging of Prostate Cancer Bone Disease: Correlation With Bone Biopsy Histological and Molecular Features.
    Invest Radiol. 2017 Sep 12. doi: 10.1097/RLI.0000000000000415.
    PubMed     Text format     Abstract available


    J Magn Reson Imaging

  22. YIM JH, Kim CK, Kim JH
    Clinically insignificant prostate cancer suitable for active surveillance according to Prostate Cancer Research International: Active surveillance criteria: Utility of PI-RADS v2.
    J Magn Reson Imaging. 2017 Sep 13. doi: 10.1002/jmri.25856.
    PubMed     Text format     Abstract available


    J Nucl Med

  23. PICCARDO A, Paparo F, Puntoni M, Righi S, et al
    64CuCl2 PET/CT in prostate cancer relapse.
    J Nucl Med. 2017 Sep 8. pii: jnumed.117.195628. doi: 10.2967/jnumed.117.195628.
    PubMed     Text format     Abstract available


    J Urol

  24. ORCZYK C, Emberton M
    Re: Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient Specific Molds to Correlate Images with Whole Mount Pathology: A. Priester, S. Natarajan, P. Khoshnoodi, D. J. Margolis, S. S. Raman, R. E. Reiter, J. Huang, W.
    J Urol. 2017 Sep 6. pii: S0022-5347(17)77256-4. doi: 10.1016/j.juro.2017.
    PubMed     Text format    

  25. GRIEBLING TL
    Re: Which Better Predicts Mortality among Older Men, a Prostate Cancer (PCa) Diagnosis or Vulnerability on the Vulnerable Elders Survey (VES-13)? A Retrospective Cohort Study.
    J Urol. 2017;198:723-724.
    PubMed     Text format    

  26. GRIEBLING TL
    Re: Comorbidity and Age Cannot Explain Variation in Life Expectancy Associated with Treatment of Non-Metastatic Prostate Cancer.
    J Urol. 2017;198:723.
    PubMed     Text format    

  27. GRIEBLING TL
    Re: Current Impact of Age and Comorbidity Assessment on Prostate Cancer Treatment Choice and Over/Undertreatment Risk.
    J Urol. 2017;198:724.
    PubMed     Text format    

  28. PENSON DF
    Re: Sharp Decline in Prostate Cancer Treatment among Men in the General Population, but Not among Diagnosed Men.
    J Urol. 2017;198:734-735.
    PubMed     Text format    

  29. TANEJA SS
    Re: Active Surveillance in Younger Men with Prostate Cancer.
    J Urol. 2017;198:741-745.
    PubMed     Text format    

  30. TANEJA SS
    Re: Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.
    J Urol. 2017;198:742-743.
    PubMed     Text format    

  31. TANEJA SS
    Re: Association between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes after 3 Years.
    J Urol. 2017;198:743-744.
    PubMed     Text format    

  32. PENSON DF
    Re: Association between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes after 3 Years.
    J Urol. 2017;198:744-745.
    PubMed     Text format    

  33. TANEJA SS
    Re: Presence of Invasive Cribriform or Intraductal Growth at Biopsy Outperforms Percentage Grade 4 in Predicting Outcome of Gleason Score 3+4=7 Prostate Cancer.
    J Urol. 2017;198:745.
    PubMed     Text format    

  34. ATALA A
    Re: Genome-Wide Association Study of Prostate-Specific Antigen Levels Identifies Novel Loci Independent of Prostate Cancer.
    J Urol. 2017;198:747.
    PubMed     Text format    


    Nat Rev Urol

  35. STONE L
    Prostate cancer: CTC phenotype informs treatment type.
    Nat Rev Urol. 2017 Sep 12. doi: 10.1038/nrurol.2017.
    PubMed     Text format    

  36. MURILLO-GARZON V, Kypta R
    WNT signalling in prostate cancer.
    Nat Rev Urol. 2017 Sep 12. doi: 10.1038/nrurol.2017.
    PubMed     Text format     Abstract available


    Oncol Rep

  37. KHURANA N, Kim H, Chandra PK, Talwar S, et al
    Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer.
    Oncol Rep. 2017 Aug 30. doi: 10.3892/or.2017.5932.
    PubMed     Text format     Abstract available


    PLoS One

  38. OPOKU-ACHEAMPONG AB, Henningson JN, Beck AP, Lindshield BL, et al
    5alpha-reductase 1 mRNA levels are positively correlated with TRAMP mouse prostate most severe lesion scores.
    PLoS One. 2017;12:e0175874.
    PubMed     Text format     Abstract available

  39. KANG M, Lee KH, Lee HS, Jeong CW, et al
    Concurrent treatment with simvastatin and NF-kappaB inhibitor in human castration-resistant prostate cancer cells exerts synergistic anti-cancer effects via control of the NF-kappaB/LIN28/let-7 miRNA signaling pathway.
    PLoS One. 2017;12:e0184644.
    PubMed     Text format     Abstract available

  40. SOUZA MF, Kuasne H, Barros-Filho MC, Ciliao HL, et al
    Circulating mRNAs and miRNAs as candidate markers for the diagnosis and prognosis of prostate cancer.
    PLoS One. 2017;12:e0184094.
    PubMed     Text format     Abstract available

  41. KARLSSON J, Gouveia-Figueira S, Alhouayek M, Fowler CJ, et al
    Effects of tumour necrosis factor alpha upon the metabolism of the endocannabinoid anandamide in prostate cancer cells.
    PLoS One. 2017;12:e0185011.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  42. TAKAYAMA KI, Suzuki T, Fujimura T, Yamada Y, et al
    Dysregulation of spliceosome gene expression in advanced prostate cancer by RNA-binding protein PSF.
    Proc Natl Acad Sci U S A. 2017 Sep 11. pii: 201706076.
    PubMed     Text format     Abstract available


    Prostate

  43. TSUMURA H, Ishiyama H, Tabata KI, Katsumata H, et al
    Impact of five-tiered Gleason grade groups on prognostic prediction in clinical stage T3 prostate cancer undergoing high-dose-rate brachytherapy.
    Prostate. 2017 Sep 14. doi: 10.1002/pros.23430.
    PubMed     Text format     Abstract available

  44. VINCENEUX A, Bruyere F, Haillot O, Charles T, et al
    Ductal adenocarcinoma of the prostate: Clinical and biological profiles.
    Prostate. 2017;77:1242-1250.
    PubMed     Text format     Abstract available

  45. PEDRAZA-AREVALO S, Hormaechea-Agulla D, Gomez-Gomez E, Requena MJ, et al
    Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer.
    Prostate. 2017 Sep 14. doi: 10.1002/pros.23426.
    PubMed     Text format     Abstract available

  46. KANAYAMA M, Hayano T, Koebis M, Maeda T, et al
    Hyperactive mTOR induces neuroendocrine differentiation in prostate cancer cell with concurrent up-regulation of IRF1.
    Prostate. 2017 Sep 14. doi: 10.1002/pros.23425.
    PubMed     Text format     Abstract available


    Urol Int

  47. ZAPALA P, Dybowski B, Poletajew S, Radziszewski P, et al
    What Can Be Expected from Prostate Cancer Biomarkers? A Clinical Perspective.
    Urol Int. 2017 Sep 15. doi: 10.1159/000479982.
    PubMed     Text format     Abstract available


    Urology

  48. GOLOMBOS DM, Ayangbesan A, O'Malley P, Lewicki P, et al
    The Role of Gut Microbiome in the Pathogenesis of Prostate Cancer: a Prospective, Pilot Study.
    Urology. 2017 Sep 6. pii: S0090-4295(17)30957.
    PubMed     Text format     Abstract available

  49. WIENER S, Haddock P, Cusano J, Staff I, et al
    Incidence of Clinically Significant Prostate Cancer after a Diagnosis of Atypical Small Acinar Proliferation (ASAP), High Grade Prostatic Intraepithelial Neoplasia (HGPIN), or Benign Tissue.
    Urology. 2017 Sep 6. pii: S0090-4295(17)30958.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: